tradingkey.logo

Mineralys Therapeutics Inc <MLYS.OQ> expected to post a loss of 98 cents a share - Earnings Preview

ReutersMay 5, 2025 8:56 PM
  • Mineralys Therapeutics Inc MLYS.OQ MLYS.O is expected to show no change in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025

  • ​LSEG's mean analyst estimate for Mineralys Therapeutics Inc is for a loss of 98 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Mineralys Therapeutics Inc is $42.00​, above​ its last closing price of $15.42. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-1.11

-1.08

-0.98

Beat

9

Sep. 30 2024

-0.87

-0.83

-1.13

Missed

-35.4

Jun. 30 2024

-0.70

-0.70

-0.83

Missed

-18.6​

Mar. 31 2024

-0.61

-0.67

-0.70

Missed

-4.8

​​Dec. 31 2023

-0.82

-0.61

Beat

26.1

Sep. 30 2023

-0.70

-0.76

-0.57

Beat

25​

Jun. 30 2023

-0.67

-0.72

-0.31

Beat

56.9

Mar. 31 2023

-0.88

-0.89

-0.51

Beat

42.7

This summary was machine generated May 5 at 20:56 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI